secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0000950170-24-059544
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enliven Therapeutics Q1 net loss $22.7M; ELVN-001 Phase 1 shows 44% MMR at 12 weeks
--------------------------------------------------------------------------------

- Net loss of $22.7M for Q1 2024 vs $14.7M in Q1 2023; cash, equivalents & marketable securities $320.5M.
- ELVN-001 Phase 1 proof-of-concept: 44% (7/16) cumulative MMR rate by week 12 in response-evaluable CML patients.
- Entered $90M PIPE financing from new/existing investors; expected cash runway into late 2026.
- Appointed Dr. Lori Kunkel to Board of Directors.
- Activated first site for ELVN-002 combo trial with trastuzumab in HER2+ cancers; first dosing expected Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000095017024059544/0000950170-24-059544-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000095017024059544/elvn-20240514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-059544

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer